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 Malaria is a devastating tropical disease, accounting for 2 million infections and 
440,000 deaths in 2015. The most effective treatment for malaria is chemotherapy to 
kill the blood stage parasite. Recent spread of drug resistance against the most effective 
anti-malarial known, raises concerns about the future efficacy of existing blood stage 
chemotherapy.  
 It is therefore necessary to identify and study unique biochemical pathways in 
the parasite that hold the potential for chemical intervention. Mitochondrial lipoylation 
in Plasmodium falciparum is one such pathway. Recent evidence suggests that 
mitochondrial lipoylation in the blood stage uses a novel redox mechanism. This 
pathway appears to be a suitable drug target for blood stage malaria and further 
characterization of the mechanisms involved are needed.  
 In this study two of the key proteins involved in this pathway, lipoate ligase 1 
(LipL1) and the H-protein, were expressed in E. coli and purified using FPLC. The purified 
proteins along with the cofactors necessary to drive the protein-protein interaction 
were screened for crystal formation in an attempt to collect x-ray diffraction data that 
could be used for structural determination. Crystals were grown and subjected to x-ray 
radiation, but produced poor quality diffraction data and no structural determinations 
could be made.  
 The dissociation constant and binding kinetics of the protein-protein interaction 
under reducing and non-reducing conditions were studied using isothermal titration 
calorimetry (ITC). Data collected from ITC experiments yielded an average dissociation 
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constant of 0.097µM under non-reducing conditions and 4.8µM under reducing 
conditions. Surface Plasmon Resonance (SPR), which uses a fraction of the protein 
sample compared to ITC, was also used to study the binding between LipL1 and the H-
protein. Data collected from SPR experiments yielded a dissociation constant of 0.39µM 
under non-reducing conditions. 
 The above dissociation constants suggest that lipoylation of the H-protein takes 
place due to its increased affinity for the LipL1-lipoyl-AMP complex, which dominates 
under non-reducing conditions. Under very reducing conditions, the LipL1-dihydrolipoyl-
AMP complex dominates and as can be inferred from the dissociation constants, binding 
and subsequent lipoylation of the H-protein is diminished allowing for binding or 
lipoylation of other substrates.   
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There have been great strides made in the reduction of malaria cases and deaths 
over the past 15 years. This reduction is due to a number of factors such as increased 
distribution and use of insecticide-treated mosquito nets (ITNs), increased coverage of 
indoor residual spraying (IRS), increased chemoprevention in pregnant women and 
children, increased distribution and use of diagnostic testing, specifically rapid 
diagnostic tests (RDTs), and increased use of artemisinin-based combination therapy 
(ACT) as antimalarial drug treatment (1).  Although there have been great reductions in 
the number of malaria cases and deaths over the past 15 years, malaria remains a 
devastating disease. The World Health Organization (WHO) estimates that there were 
214 million malaria cases and 440,000 malaria related deaths in 2015 and nearly 70% 




Malaria is a disease caused by the intracellular, protozoan parasites of the genus 
Plasmodium. Humans can become infected with the Plasmodium parasite when they are 
bitten by an infectious female Anopheles mosquito. Currently, five species of 
Plasmodium: P. falciparum, P. knowlesii, P. malariae, P. ovale and P. vivax are known to 
cause disease in humans. Of the five species of Plasmodium that infect humans, P. 
falciparum accounts for the majority of malaria related deaths (1).  
To say that the lifecycle of the Plasmodium parasite is complex is an 
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understatement. Upon probing for a blood meal, the infectious female Anopheles 
mosquito releases the sporozoite form of the parasite from her salivary gland into the 
human host via her proboscis (figure 1). Sporozoites migrate through the human 
bloodstream into the liver where they invade hepatocytes. Once in the hepatocyte, the 
sporozoite undergoes replication for 2-16 (species dependent (sd)) days until thousands 
of merozoites are released into the blood stream. These merozoites invade 
erythrocytes, where they undergo schizogony to produce 8-32 (sd) new merozoites per 
infected erythrocyte. The infected erythrocyte ruptures 48-72 (sd) hours’ post-invasion 
releasing merozoites which invade more erythrocytes and perpetuate the asexual 
erythrocytic or blood stage cycle (2). A subset of merozoites differentiate into male and 
female gametocytes within the erythrocyte. These non-replicating, asymptomatic 
gametocytes are responsible for parasite transmission back into the mosquito vector 
upon ingestion of a blood meal. Once inside the mosquito midgut, the gametocytes 
differentiate into male and female gametes and fuse to form a zygote. The zygote 
further develops into another form of the parasite known as an ookinete. Once formed, 
the ookinete moves through the mosquito mid-gut epithelium and forms an oocyst on 
the outer midgut epithelium. Thousands of sporozoites are produced in each oocyst and 
after rupture of the oocyst they migrate to the mosquito salivary gland where they wait 
to be transmitted to the human host during the next blood meal (2). 
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         Figure 1.  Lifecycle of the human malaria parasite (2). 
 
This complicated two organism life cycle offers many hurdles in the pursuit to 
control malaria, however, an optimist would contest that it also offers many 
opportunities to disrupt the parasite at various stages during its lifecycle. There are 
numerous labs dedicated to understanding the interplay of the parasite and its host 
environment in all stages of the lifecycle. The research in the laboratory of Dr. Sean 
Prigge is primarily dedicated to studying the blood stage of P. falciparum, since this is 
the only stage that causes the clinical symptoms of malaria in people.  The work 
presented in this thesis is concentrates on the mechanism of protein lipoylation in the 
mitochondrion – a process known to be essential for the survival of blood stage P. 
falciparum parasites.  
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Drug Resistance in Malaria 
  
One of the remaining challenges for malaria control and elimination is the 
geographical spread of drug resistant parasites (1). Drugs have been used to prevent 
and treat persons infected with malaria for centuries. Chloroquine (CQ), an antimalarial 
first synthesized in the 1930’s, became widely used in the early 1950’s due its safety, 
low cost, and efficacy.  CQ resistant parasites were anecdotally reported in 1957 and in 
1960 the first CQ resistant parasites were confirmed in Colombia and also along the 
Cambodia-Thailand border. Over the next three decades CQ resistant parasites spread 
from the Cambodia-Thai border throughout Southeast Asia, Micronesia, Melanesia, 
India, and into Africa. By 1987 CQ resistant parasites had been confirmed in more than 
40 countries. The emergence of CQ resistant parasites reduced the therapeutic efficacy 
of CQ as an antimalarial in these regions, but also severely hampered early malaria 
eradication efforts (2–4). 
Sulfadoxine-pyrimethamine (SP), a safe and cheap antimalarial treatment, began 
seeing widespread use as CQ resistant parasites began to spread. Sulfadoxine and 
pyrimethamine target and inhibit two enzymes involved in folate metabolism, a 
different mechanism of action than CQ (5). SP was introduced in Thailand in the late 
1960’s and its use spread throughout Southeast Asia and South America in the 1970’s 
and eventually saw use in Africa in the early 1980’s (6–9). Just as was seen with CQ, 
increased use of SP led to increased parasite resistance; in the 1980’s SP failure rates 
were between 60-70% in parts of Thailand, in the 1990’s many endemic regions of South 
America could no longer effectively use SP treatment, and in Africa SP resistance was 
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first documented in the 1980’s and rapidly spread from East Africa into West Africa (7–
11).   
Artemisinin was first reported to cure malarious patients in China in 1979 (12). It 
was first introduced on the world stage in the mid 1990’s as multidrug resistant 
parasites had developed in Southeast Asia. Artemisinin and its derivatives clear blood 
stage parasites more rapidly than any other currently available antimalarials and 
artemisinin in combination with other antimalarial drugs (called ACT) has been 
recommended by the WHO as a treatment for drug resistant P. falciparum malaria since 
2001 (13, 14). The WHO has also strongly recommended that artemisinin only be used in 
combination with other antimalarials and in 2006 urged artemisinin manufacturers to 
stop marketing artemisinin monotherapies; both of these recommendations were made 
to help combat the possibility of artemisinin resistant parasites (4, 14). Despite the 
WHOs best efforts, ACT resistant parasites have recently emerged in Southeast Asia (13, 
15, 16).  
The possibility of ACT resistant parasite spreading into other parts of the world 
poses a major threat to global malaria control efforts, as ACT is one of the last remaining 
treatments for multi drug resistant P. falciparum malaria.  In an effort to combat the 
spread of malaria, it is necessary to find novel or existing compounds that lack adverse 
effects in the human host, but are effective at clearing parasites during blood stage 
infection. One approach to uncovering these compounds is the biochemical and 
structural characterization of pathways that are unique to the parasite.  One particular 
pathway of interest as a target for drug intervention is the mitochondrial lipoylation 
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pathway in P. falciparum.   
Alpha Lipoic Acid 
-lipoic acid is an eight carbon cyclic disulfide derivative of octanoic acid (figure 
2). Above pH 4.7 the deprotonated and charged form, lipoate, exists as the dominate 
species (17). -lipoic acid was first crystallized from liver extracts in 1951 and at the 
time was thought to be a novel B vitamin due to its ubiquity in biological sources, high 
activity, and evidence of its catalytic role in the oxidative decarboxylation of pyruvate 
(17). The notion of lipoate as a B vitamin has since been abandoned as there is no 
known human disease associated with lipoate deficiency and strong evidence exists for 
mammalian synthesis of lipoate (18). Nevertheless, lipoate plays a key role as a cofactor 
in several metabolic pathways.  
 
 
Figure 2. Octanoic acid derivatives. (A) Octanoic acid in its deprotonated form. (B) The R  
stereoisomer of lipoate. (C) The structural analogue 8-bromooctanoate has been used in  
parasite growth inhibition studies. (D) The reduced form of lipoate, dihydrolipoate.    
 
Synthesis and Scavenging of Lipoate  
 Lipoylation is the term used to describe the posttranslational modification or 
covalent attachment of lipoate to proteins. Two mechanisms of lipoylation are known to 
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exist: lipoate scavenging, which refers to the ligation of free exogenous lipoate to a 
protein and lipoate synthesis, which refers to the generation of protein bound lipoate 
from an 8-carbon, octanoylated precursor (19).  
 Lipoate metabolism is present in most bacterial, fungal, and protozoan 
pathogens and a thorough review of the nuances of the lipoylation strategies and 
lipoylated proteins present in these pathogens can be found in reference (20). The two 
mechanisms of lipoylation have been best characterized in E. coli and will be described 
here, before introducing the pathways in Plasmodium.  
 In E. coli, lipoate scavenging occurs through the ligation of free exogenous 
lipoate by a lipoate ligase, LplA, to a conserved lysine residue on either of the apo-E2 or 
apo-H-protein subunits of the known lipoylated complexes (described below) (21). All 
lipoate ligases work in similar manner to catalyze a two-step ATP dependent reaction: 1. 
ATP activates free lipoate to form lipoyl-AMP, releasing pyrophosphate. 2. Upon binding 
of apo-E2 or apo-H-protein subunits, the activated carbonyl of lipoyl-AMP forms a 
lipoamide bond with a conserved terminal lysine residue on these proteins, releasing 
AMP and the now lipoylated holo-E2 or holo-H-proteins (21). It has also been shown 
that LplA can use octanoate and 8-bromooctanoate as a substrate in lieu of lipoate, with 
8-bromooctanoate resulting in E. coli growth inhibition (21–23).   
 Lipoate synthesis in E. coli is catalyzed by an octanoyl transferase, LipB, which 
transfers an octanoyl group from octanoyl acyl carrier protein to the apoproteins, E2 or 
H (19). After this transfer, a lipoate synthase, LipA, inserts two sulfur atoms on the 
octanoylated proteins forming the dithiolane ring of lipoate (19, 22, 24). 
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 It is worth noting that the lipoyl domain of the E2 subunits and the H-protein 
share structural similarities, as would be expected considering that they are modified by 
the same lipoylation enzymes (27). 
 
Lipoate’s Dual Role 
Lipoate plays two major roles in the cell. First, lipoate is a unique antioxidant as 
it confers free radical protection in both its oxidized and reduced forms. The lipoate – 
dihydrolipoate redox couple and its wide ranging antioxidant properties can be 
reviewed in references (25) and (26). Second, lipoate serves as a key co-factor in several 
multi-enzyme complexes involved in metabolism. Three of these five complexes are -
ketoacid dehydrogenases, the fourth is an acetoin dehydrogenase, and the fifth is the 
glycine cleavage complex (GCV) or glycine cleavage system (GCS) (20).  
The three -ketoacid dehydrogenase complexes are pyruvate dehydrogenase 
(PDH), -ketoglutarate dehydrogenase (KDH), and branched-chain -ketoacid 
dehydrogenase (BCDH). These three -ketoacid dehydrogenase complexes as well as 
the acetoin dehydrogenase complex share a three subunit architecture with the three 
subunits commonly referred to as E1, E2, and E3 (27, 28). These dehydrogenase 
complexes are massive; the bovine heart PDH complex, for example, is 9.5 MDa and 
consists of 30 copies of the E1 heterotetramer, 12 copies of the E3-binding protein 
monomer, and 12 copies of the E3 homodimer all arranged around a 20 copy core of the 
E2 trimer in an icosahedral configuration (29). The GCS has a much different 
architecture as no stable complex is formed, it is composed of four loosely associated 
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and independent proteins, known as P, T, H and L (30). 
The -ketoacid dehydrogenase complexes all work in a similar manner in that 
they catalyze the decarboxylation of -ketoacids to produce acyl-coenzyme A (acyl-
CoA), NADH, and CO2 by related reaction mechanisms (27). Essentially, the reactions 
begin with the decarboxylation of the substrate by the E1 subunit and acylation of one 
of the sulfur atoms in lipoamide, leaving the second sulfur reduced. The E2 subunit 
active site catalyzes the transfer of the acyl moiety from the lipoamide to CoA. The E3 
subunit then oxidizes the reduced dihydrolipoamide back to lipoamide in a NAD-
dependent reaction (27) (figure 3A).  The various substrates and fates of the -ketoacid 




Substrate Products Pathways 
PDH pyruvate Acetyl-CoA TCA cycle 
Fatty acid synthesis 
Fatty acid elongation 
Isoprenoid biosynthesis 
KDH -ketoglutarate Succinyl-CoA TCA cycle 
Heme biosynthesis 
Amino acid biosynthesis 






TCA cycle intermediates 
Branched chain fatty- 
    acid biosynthesis 
Table 1.  -KDH complex substrates. The various substrates of the -KDH complexes, the products that are 
produced and the relevant metabolic pathways. 
 
The glycine cleavage complex catalyzes the reversible decarboxylation of glycine 
into CO2, NADH, NH3, while transferring a methylene group to tetrahydrofolate (THF) 
forming 5,10-CH2-THF (30). 5,10-CH2-THF then serves as a one-carbon donor molecule, 
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used by the cell primarily during the synthesis of pyrimidine nucleotides (31) (figure 3B).  
          
 
Figure 3. Reactions of lipoylated complexes (20). (A) The -Ketoacid dehydrogenase complexes have 
analogous reaction mechanisms. The E1 subunit decarboxylates the substrate and transfers the acyl group 
to lipoamide on the E2 subunit. The E2 subunit transfers the acyl group to coenzyme A. Lipoate is 
regenerated through reduction of NAD+ by the E3 subunit. (B) The Glycine cleavage complex catalyzes the 
reversible oxidative decarboxylation of glycine into carbon dioxide, ammonia, and a methylene group.  The 
H-protein serves as a mobile substrate, shuttling between the active sites of the P, T and L proteins.  
 
 
Lipoylation pathways in P. falciparum 
 
 The P. falciparum genome encodes four proteins that are expressed and 
lipoylated in blood stage parasites, the E2 subunits of the PDH, KDH, BCDH and the H-
protein (32–34). The E2 proteins of the KDH and BCDH contain a single lipoyl domain 
while the PDH E2 contains two lipoyl domains (35). The lipoylated proteins are 
partitioned in two different organelles within the parasite, the apicoplast and 
mitochondrion (36).  
 The apicoplast harbors a lipoate biosynthesis pathway that has been shown to 
be superfluous during blood stage infection, but critical for parasite development during 
the liver stage (34, 37, 38).  The PDH complex is localized solely to the parasite 
apicoplast and the lipoylation of the PDH E2 subunit proceeds in a manner analogous to 
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E. coli lipoate synthesis, with PfLipB acting as the octanoyl transferase and PfLipA 
serving as the lipoate synthase (35, 36). The P. falciparum LipB gene has been 
successfully disrupted with no deleterious growth defects on blood stage parasites, 
suggesting that the P. falciparum lipoate synthesis pathway is dispensable during the 
blood stage and therefore would not make a suitable drug target. 
 The parasite is dependent upon host scavenged lipoate in order to lipoylate the 
E2 subunits of the BCDH and KDH as well as the H-protein of the GCS, all three of which 
are found exclusively in the mitochondrion (33, 36, 39). Substrate lipoylation in the 
parasite mitochondrion is dependent upon two enzymes, lipoate ligase 1 (LipL1) and 
lipoate ligase 2 (LipL2). LipL1 is strictly localized to the mitochondrion, while LipL2 is 
found in both the mitochondrion and the apicoplast (34, 36). Both LipL1 and LipL2 genes 
appear to be refractory to disruption, suggesting that the lipoate scavenging pathway is 
necessary for parasite blood stage development and therefore would make an attractive 
target for therapeutic intervention (40, 41). The evidence for the necessity of lipoate 
scavenging is further strengthened by inhibition studies conducted with the lipoate 
analogue 8-bromooctanoate (8-BrO) (figure 2). Treatment of parasites with 8-BrO, 
which is presumed to enter the parasite via the same transporter as lipoate, interferes 
with the integration of scavenged lipoate and results in blood stage growth inhibition 
(33).    
 A recently published paper from our lab provides evidence for two distinct 
mitochondrial lipoylation pathways in P. falciparum.  The findings also suggest that the 
switch between these pathways is dependent upon the redox conditions within the 
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mitochondrion, a mechanism that has not been described in any other organism (42). 
Under slightly reducing conditions LipL1 works independently to lipoylate the H-protein. 
However, under strong reducing conditions LipL1 and LipL2 work in conjunction to 
almost exclusively lipoylate the E2 subunits of the BCDH and KDH complexes, while the 
H-protein shows almost no lipoylation as visualized by western blot analysis in (42). The 
current model for P. falciparum mitochondrial lipoylation can be seen in figure 4.   
 
 
Figure 4 – Lipoylation via lipoate scavenging in P. falciparum. Under less reducing conditions LipL1 
lipoylates the H-protein. Under conditions where lipoate is reduced to dihydrolipoate LipL1 and LipL2 work 
in concert to lipoylate the E2 subunits of the BCDH and KDH complexes.   
 
Structural studies of E. Coli lipoylation  
 A key to understanding what may be going on in the P. falciparum 
mitochondrion can be found if we turn our attention back to the E. coli lipoylation 
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machinery. The crystal structure of the E. Coli lipoate ligase, LplA, in complex with lipoyl-
AMP has been determined at 2.05 Å as well as the ternary structure of LplA, octanyl-
AMP, and the E. coli H-protein at 3.00 Å (43). Their structures show that upon activation 
of lipoate to lipoyl-AMP, LplA undergoes a structural rearrangement where the C-
terminal domain rotates by 180o. It is only after this structural rearrangement that 
binding and subsequent lipoylation of the H-protein can occur.  
 
Aims of the project. 
 
 I hypothesize based on evidence from the Afanador (42) paper that PfLipL1 
undergoes different structural rearrangements depending on whether it binds lipoyl-
AMP or the reduced dihydrolipoyl-AMP. This structural difference is the molecular 
switch causing LipL1 to recruit either LipL2 (for the lipoylation of KDH and BCDH), or the 
H-protein. I would therefore predict that the H-protein would bind tightly to a LipL1/ 
lipoyl-AMP complex, but not to a LipL1/ dihyrolipoyl-AMP complex. Unfortunately, 
formation of the ternary H-protein/LipL1/lipoyl-AMP complex should rapidly lead to 
product formation. By mutating the site of lipoylation on the H-protein, from lysine to 
alanine (HK96A), we can theoretically abrogate its lipoylation while still being able to 
study the binding.  
 Using the HK96A mutant, I attempted to crystallize the H-protein/LipL1/lipoyl-
AMP complex in order to determine its structure using x-ray crystallography. I also set 
out to determine the dissociation constant of HK96A for the LipL1/lipoyl-AMP complex 
under reducing and non-reducing conditions using isothermal titration calorimetry and 
surface plasmon resonance. The work is done in an attempt to better characterize and 
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understand the mechanisms of mitochondrial lipoylation in Plasmodium falciparum, as 
this pathway is unique to the parasite and appears to be a good target for drug 








 Expression plasmid pMALcHT-Hprot (42), encoding residues E35-K200 (lacking 
the predicted N-terminal mitochondrial transit peptide) of the Pf H-protein 
(PF3D7_1132900) was subjected to site directed mutagenesis (SDM) in order to mutate 
the conserved lysine residue at position 96 to an alanine residue for binding studies. 
pMALcHT-Hprot was subjected to PCR amplification with forward and reverse primers 
coding for the lysine to alanine mutation (see appendix - primers). The resulting PCR 
reaction mixture was incubated with DpnI endonuclease at 37oC for 1hour to digest any 
of the template pMALcHT-Hprot plasmid. The amplicons were then subjected to ethanol 
precipitation and re-suspended in H2O. Plasmids were transformed into BL21-Star (DE3) 
cells (Invitrogen), grown for 1 hour in SOC media at 370C, 250rpm and plated on LB agar 
+ carbenicillin to select for the pMALcHT plasmid. After 24 hours at 37oC colonies were 
selected, grown in 5ml of circle grow media + carbenicillin overnight at 370C, 250rpm. 
Plasmids were isolated using Qiagen plasmid mini-prep protocol and sent for DNA 
sequencing for verification. One of the three colonies sent for sequencing was verified 
as having the lysine to alanine mutation at position 96. This plasmid was renamed 
 15 
pMALcHT-HK96A for this study. Expression plasmid pMALcHT-LipL1 (42) was used 
without modification for this study.  
 A plasmid encoding the Pf H-protein (residues E35-K200) with a lysine to 
methionine mutation at position 96 (HK96M) fused to Pf LipL1 (minus the mitochondrial 
targeting sequence) via a 17 amino acid linker region was purchased from GeneArt 
(appendix, figures 12, 13). This fusion protein construct was designed to be used for 
crystallization studies and was named pMK HK96M-LipL1 for this study. We used pMK 
HK96M-LipL1 to generate a similar plasmid with the K96A mutation instead of K96M. 
pMK HK96M-LipL1 was incubated with restriction enzymes PvuI-HF and AatII overnight 
at 37oC to remove a small sequence including the lysine to methionine mutation at 
position 96. One hour prior to gel purification of the cut plasmid, 0.5µl of Shrimp 
Alkaline Phosphatase (NEB) was added to the reaction to remove the 5’ and 3’ terminal 
phosphates.  The cut pMK plasmid was visualized on a 1% agarose gel and the resulting 
band was excised and gel purified using a Qiagen QIAquick gel extraction kit. Duplex 
DNA encoding the K96A mutation was formed from adaptamer primers (see appendix). 
1µL of 100µM forward and reverse HK96A adaptamer primers were mixed with 1µL of 
10x PCR buffer (NEB) and 8µL of water. This mixture was placed in a heat block at 92oC 
for one minute and allowed to cool/anneal at room temperature. After cooling, the 
duplex DNA insert was diluted to a concentration of 1µM and 0.1µM.  A 12µL ligation 
reaction was initiated using 6µL of New England Biolabs (NEB) 2x ligase buffer, 1.2µL 
quick ligase (NEB), and 4.8µL of the cut pMK plasmid. After mixing, this 12µL reaction 
was immediately split into 3 equal parts and incubated with 2µL H20 (control), 2µL of 
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1µM HK96A adaptamer, and 2µL of 0.1µM HK96A adaptamer. After 15 minutes at room 
temperature, these ligation reactions were transformed into Top10 E. coli cells 
(Invitrogen) as described above.  Plasmids from carbenicillin-resistant colonies were 
isolated and sequence verified as described above. The resulting plasmid was named 
pMK HK96A-LipL1.  
 The protein coding portions of the pMK plasmids were subcloned into the 
expression plasmid pMALcHT (44) for protein production. pMK HK96M-LipL1 and pMK 
HK96A-LipL1 were digested with EcoRI and HindIII overnight at 37oC to remove the H-
LipL1 fusion sequence from the plasmid. The digestion products were visualized on a 1% 
agarose gel and the band corresponding to the H-LipL1 sequence was excised and gel 
purified as described above.  This sequence was then ligated into the pMALcHT vector 
which had also been digested with EcoRI and HindIII. The sequences were verified and 
the resulting plasmids were renamed pMALcHT HK96M-LipL1 and pMALcHT HK96A-
LipL1.   
 The HK96A-LipL1 fusion construct was designed with multiple restriction enzyme 
sites in the 17 amino acid linker region between the two proteins in order to have the 
option to adjust the length of the linker (appendix, figure 12). The restriction enzymes 
SpeI and NheI were used to cut out a 15 amino acid stretch of this linker. The cut 
plasmid was visualized on a 1% agarose gel, the band was cut out, gel purified, and 
subjected to ligation. The sequence was verified and the product was renamed 
pMALcHT HK96A-LipL1 d15. Another truncation was made in a similar manner with the 
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restriction enzyme KpnI-HF, removing 9 amino acids from the linker region. The 
sequence of this construct was verified and was renamed pMALcHT HK96A-LipL1 d9.  
 Expression plasmid pMALcHT (33, 44) was used to express LipL1, HK96A, HK96M-
LipL1 fusion protein, and HK96A-LipL1 fusion protein as maltose binding protein (MBP) 
fusion proteins with a linker region composed of a tobacco etch virus (TEV) protease cut 
site followed by a six histidine affinity tag.   
Protein expression and purification  
 Plasmids pMALcHT-LipL1, pMALcHT-HK96A, pMALcHT HK96M-LipL1, pMALcHT 
HK96A-LipL1, pMALcHT HK96A-LipL1 d15, and pMALcHT HK96A-LipL1 d9 were 
transformed into BL21-Star (DE3) cells (Invitrogen) and co-transformed with the pRIL 
plasmid isolated from BL21- CodonPlus-RIL cells (Agilent) and plasmid pRK586 encoding 
the Tobacco Etch Virus (TEV) protease (45), as previously described (33, 42). These cells 
produce the protein of interest fused to an amino-terminal six histidine-tag (the MBP 
tag is cleaved in vivo by TEV protease). Transformed cells were grown in 500mL of 
Terrific Broth (TB) at 250rpm, 37oC until OD (600nm) = 3.0. The expression of 
recombinant proteins was induced by the addition of 0.4mM IPTG and cultures were 
incubated for 10 hours at 20oC. Proteins were harvested by pelleting cultures at 
4200rpm for 20 minutes. Cell pellets were re-suspended in approximately 50mL of 
buffer containing 20mM HEPES, 300mM NaCl, 20mM imidazole, pH 7.5 and 
supplemented with EDTA free protease inhibitor cocktail, (Complete Protease Mini; 
Roche Diagnostics Corp.). Re-suspended cells were cooled on ice and lysed via 
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sonication at 33% amplitude, a pulse of 0.5s on, 0.5s off, in three 1-minute iterations, 
with one minute of cooling between sonication. Lysed cells were centrifuged at 
19000rpm for 25 minutes. The supernatant was then subjected to metal chelate 
chromatography (HisTrap HP 5mL). Captured protein was gradient eluted with 1M 
imidazole pH 8.0 into 5mL fractions. Fraction samples were analyzed via SDS-PAGE. 
Fractions containing the protein of interest were consolidated and subjected to 
desalting/buffer exchange (20mM HEPES, 50mM NaCl, pH 7.5 for HK96A and LipL1 or 
50mM MES, 50mM NaCl, pH 6.0 for H-LipL1 fusion) with 2x HiPrep 26/10 columns with 
the flow through passing directly onto ion exchange columns (HiTrap SP FF 5mL column 
for LipL1 and H-LipL1 fusion: HiTrap Q HP 5mL column for HK96A). Proteins were 
gradient eluted from ion exchange columns with 20mM HEPES, 1M NaCl, pH 7.5 for 
HK96A and LipL1 or 50mM MES, 1M NaCl, pH 6.0 for H-LipL1 fusion and collected in 5mL 
fractions.  Fraction samples were analyzed via SDS-PAGE. Fractions containing the 
protein of interest were consolidated and subjected to gel filtration/size exclusion 
chromatography on a HiPrep 26/60 Sephacryl S-100 high resolution column. Proteins 
were collected in 5 mL fractions that were analyzed via SDS-PAGE. Fractions containing 
the protein of interest were consolidated and concentrated using Amicon Ultra 
centrifugal filters, 10kD MWCO and 30kD MWCO for HK96A and LipL1, respectively. 
Purity was confirmed by SDS-PAGE using Coomassie staining. Stock protein 
quantification was performed using a Nanodrop ND-2000 spectrophotometer at 280nm 
absorbance. The absorbance values along with the predicted extinction coefficient 
obtained through the ExPASy protparam tool (http://web.expasy.org/protparam) were 
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used to calculate the protein concentration. Concentrated protein stocks were used 
immediately or stored at -80oC. All purification techniques were conducted at 4oC using 
an AKTA FPLC system. All columns used were manufactured by GE Healthcare Life 
Sciences. 
Crystallization 
 Purified LipL1 and HK96A were thawed on ice and spun at 13000rpm for 15 
minutes at 4oC in a tabletop centrifuge to pellet any aggregates, the supernatant was 
transferred to a clean Eppendorf tube after centrifugation. Purified, concentrated LipL1, 
HK96A, ATP and R-Lipoic acid were combined into a master mix with final 
concentrations of 100µM, 130µM, 1mM, and 130µM, respectively. 
 Initial crystal screening conditions were performed using a 96-well 3 sitting drop 
Intelli-Plate (Art Robbins Instruments). Crystals were identified from a screen set up 
with 200nL of the above master mix and 200nL reservoir using a Mosquito crystallization 
robot (TTP Labtech). The Hampton Crystal Screen, MORPHEUS protein crystallization 
screen (MRC Labs), and the Wizard Classic crystal screen (Rigaku) were used in the initial 
screening conditions.  Crystals were observed in the Hampton crystal screen, conditions 
6, 12, and 46. Crystal optimization was attempted around these conditions using a 24-
well 4 sitting drop Intelli-Plate with reservoir containing 500µL of mother liquor. Sitting 
drops contained 1µL of the above master mix and 1µL of reservoir solution. All trays 
were covered and placed in 20oC to equilibrate. See appendix for optimization 
conditions. Crystal optimization was unsuccessful. Initial screen crystals were mounted 
 20 
in a 0.1mm nylon cryoloop (Hampton Research) and flash frozen directly in liquid 
nitrogen before shipping to the Stanford Synchrotron Radiation Lightsource (SSRL) for 
data collection.  
 Purified HK96A-LipL1 fusion protein was thawed on ice and spun at 13000rpm 
for 15 minutes at 4oC in a tabletop centrifuge to pellet any aggregates and the 
supernatant was transferred to a clean Eppendorf tube after centrifugation. Purified, 
concentrated HK96A-LipL1, ATP and R-Lipoic acid were combined into a master mix with 
final concentrations of 60µM (3.2 mg/mL), 1mM, and 100µM, respectively. Initial 
screening conditions were carried out as described above using the following screens: 
Hampton Crystal Screen, MORPHEUS protein crystallization screen (MRC Labs), Wizard 
Classic I and II crystal screens (Rigaku), PEGs Suite (Qiagen), Classics Suite (Qiagen). No 
crystals were observed in any of these conditions. Optimization was not attempted. 
Isothermal Titration Calorimetry 
 HK96A and LipL1 were thawed on ice and dialyzed overnight at 4oC in 1L of 
50mM TRIS-HCl pH 7.4, 150mM NaCl using 3,500 molecular weight cut off Slide-A-Lyzer 
dialysis cassettes (Pierce). ITC experiments were carried out using a MicroCal VP-ITC 
calorimeter.  A titrant containing 20-fold molar excess of HK96A was titrated into a 
1.4mL sample of 2µM LipL1 at 25oC. Both titrant and sample cell solutions contained 
100µM ATP, 100µM MgCl2, and 100µM R-lipoic acid. For one experiment, 5mM TCEP 
was added in addition to the above small molecules. A single 2µL injection followed by 
twenty-nine 5µL injections was used for each experiment. The baseline was corrected 
manually and the corrected data were fit to a single-site binding model using Origin 
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software. Experiments not containing TCEP were carried out in triplicate and the 
experiment containing 5mM TCEP was performed only once due to limited quantities of 
HK96A.  
Surface Plasmon Resonance 
 SPR data was collected on a Biacore 3000 instrument. All protein solutions were 
spun at 13000rpm for 15 minutes at 4oC in a tabletop centrifuge to remove any 
aggregates prior to data collection. All buffers were filtered through a 0.22-micron 
sterile filter device and degassed prior to use. Each time a new sensor chip was docked 
or running buffer was replaced, the system was primed three times to flush and 
equilibrate all internal pumps, tubing and chambers. Purified, concentrated LipL1 or 
HK96A was diluted to 20-50µg/ml in 200µL of 10mM sodium acetate buffer at pH 6.5, 
6.0, 5.5, 5.0, 4.5, 4.0 and pH scouting for optimal pre-concentration conditions on 
sensor chips CM5 and CM3 was performed. This procedure identifies the pH conditions 
that maximize protein accumulation on the sensor chip surface due to electrostatic 
interactions between the protein to be bound (ligand) and the carboxymethylated 
dextran (pKa = 3.5) on the sensor chip surface. Inspection of the sensorgram during pre-
concentration will indicate what pH is ideal for covalent immobilization, but also at what 
pH, if any, your protein may be denaturing and aggregating on the sensor surface. This is 
indicated by a persistent response on the sensor surface after the pre-concentration 
step has completed.  Sodium acetate pH 5 was determined to be the best pre-
concentration buffer for immobilization of HK96A, while sodium acetate pH 6 was the 
best pre-concentration buffer for LipL1. During pre-concentration at pH 5.5 or below, 
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LipL1 became “stuck” to the sensor chip surface and was unable to be removed even 
after harsh treatment with 50mM NaOH and 0.5% SDS. HK96A showed no indications of 
denaturation during pre-concentration.  
 HK96A or LipL1 were immobilized to the surface of a particular flow cell via 
amine coupling with 0.4M EDC/0.1M NHS using the Biacore surface preparation wizard. 
Coupling reactions were quenched with 1M ethanolamine pH 8.5. Chips were allowed to 
equilibrate for at least 2 hours in running buffer at a flow rate of 5µL/min following the 
coupling procedure. The reference flow cell was subjected to the same EDC/NHS 
coupling chemistry and ethanolamine quenching as the experimental flow cell, however 
no ligand was ever bound to the surface of the reference flow cell. The analyte was 
diluted in running buffer and a series of 2 fold dilutions were performed. Binding 
experiments were performed at a flow rate of 30µL/min, analyte injections were carried 
out using the kinetic injection (KINJECT) command in order to minimize analyte 
dispersion within the flow chambers prior to reaching the flow cell, an association time 
of 60 seconds (minimum), and a dissociation time of 120 seconds (minimum). 
Regeneration conditions could not be experimentally determined, therefore, after the 
dissociation step in each injection cycle, the flow rate was increased to 50µL/min for 10 
minutes prior to the next injection. This long wait time was added in order to allow for 
continued dissociation of the analyte ligand complex. Every binding experiment began 
with three blank injections of running buffer, that served to “warm-up” the instrument 
as well as provide a valuable second reference during data analysis. A single running 
buffer blank injection was also included in between the analyte concentration series 
 23 
injections.  
 Data was analyzed using Scrubber (BioLogic) software. To correct for non-specific 
binding and baseline drifts, a double referencing method was applied using the 








 Typical yield from a 2 x 500mL Terrific Broth preparation of HK96A is 250µL at 
2.0 mg/mL. Typical yield from a 2 x 500mL Terrific Broth preparation of LipL1 is 1mL at 8 
mg/mL. Both proteins appear to be greater than 90% pure (figure 5c). Both HK96A and 
LipL1 elute well past the void volume (90mL) of the 26/60 Sephacryl S100 column (figure 
5a and 5b), indicative of a protein that has retained its native conformation and has not 
aggregated to form a large particle. 
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Figure 5 – HK96A and LipL1 protein purification.  (A) Typical gel filtration elution profile for HK96A, in this purification 
fractions A9-A12 (green lines) were pooled and concentrated. HK96A begins to elute around 120mL. (B) Typical gel 
filtration elution profile for LipL1, fractions A9-B2 were pooled and concentrated. LipL1 begins to elute around 130mL. 
(C) SDS-PAGE gel of purified, concentrated HK96A and LipL1.  Lane 1- ladder, Lane 2- Purified HK96A, Lane 3- Purified 
LipL1.   
 
 Typical yields from a 4L LB broth preparation of HK96A-LipL1 full length fusion 
protein was 1.1mL at 7.4 mg/mL. Typical yields from a 2L LB broth preparation of 
HK96A-LipL1 d15 fusion protein was 1.5mL at 2.1 mg/mL. The H-protein (19.2kD) has a 
theoretical isoelectric point of 4.74, while LipL1 (41.1kD) has a theoretical isoelectric 
point of 8.51. I assumed that the H-protein and LipL1 in the fusion protein construct 
would behave as independent globular proteins. After metal chelate chromatography 
using the HisTrap column, I chose to take advantage of the larger positively charged 





could increase the purity of the fusion protein during elution from the SP column, when 
compared to 20mM HEPES at pH 7.5 which was the buffer used during the ion exchange 
step for each of the individual proteins. The HK96A-LipL1 full length and HK96A-LipL1 
d15 fusion proteins can be seen below in figure 6. Neither of these protein constructs 
were subjected to size exclusion chromatography.  
 
 
Figure 6 – Fusion protein purification. SDS-PAGE gel of purified HK96A-LipL1 fusion protein.  Lane 1 is the ladder. Lane 
2 is the f𝑢𝑙l length HK96A-LipL1 fusion protein. Lane 3 is the HK96A-LipL1 d15 fusion protein. The predicted size of the 
HK96A-LipL1 fusion protein is 61,700kD while the HK96A-LipL1 d15 fusion protein is 60300kD. Lanes represent proteins 






 Four LipL1/lipoyl-AMP/HK96A complex crystals were sent to SSRL, but did not 
produce a diffraction pattern of significant quality and therefore could not be used for 
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further structural studies.  On a positive note, the diffraction pattern was not that which 
is characteristic of a salt crystal. Upon return of the crystals from the SSRL, they were 
washed and subjected to SDS-PAGE in an attempt to visualize which protein(s) actually 




Figure 7. LipL1-HK96A protein complex crystals. (A) One of two presumed protein complex crystals grown in Hampton 
Research Crystal Screen (HR), condition #12. (B) The second of two presumed protein complex crystals grown in HR, 
condition #12. (C) Sole crystal grown in HR, condition #46. (Not pictured crystal grown in HR, condition #6 – 0.2M 




Isothermal Titration Calorimetry 
  
   Prior to adding 40µM HK96A into the injection syringe and 2µM LipL1 into the 
sample cell, both proteins were incubated with 100µM ATP, 100µM MgCl2, and 100µM 
R-lipoic acid for 10 minutes. The small molecules were added to LipL1 in order to allow 
the formation of the lipoyl-AMP conjugate. The small molecules were added to HK96A 
in order to minimize the heat of dilution during the titration.  
 The average dissociation constant for the HK96A with LipL1/lipoyl-AMP 
interaction under non-reducing conditions (figure 8) was determined to be 0.097µM. 
A B C 
0.2M MgCl2 Hexahydrate 
0.1M HEPES pH 7.5 
30% v/v 2-propanol 
0.2M MgCl2 Hexahydrate 
0.1M HEPES pH7.5 
30% v/v 2-propanol 
0.2M Calcium Acetate hydrate 
0.1M Sodium  
cacodylate trihydrate pH 6.5 
18% w/v PEG 8000 
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The dissociation constant for this interaction under reducing reductions (figure 9) is 
presented here as 4.8µM. The experiment under reducing conditions was only 
performed once due to limited amounts of purified HK96A. Table 8 (appendix) 
summarizes the data collected from the successful ITC. 
 
       
        Figure 8 – ITC binding data – non-reducing conditions. (A) The binding isotherm (red) is fit to the integrated  
        peaks (B - top panel) using a 1:1 binding model. The KD for this experiment is 0.142µM. (B) Top panel – Each  
       peak represents the heat released, due to binding, for each injection of HK96A into LipL1. As LipL1 becomes  
       more saturated with each subsequent injection of HK96A, less binding and therefore less heat of binding can  
       be measured until the only the heat of dilution is measured. (B) Bottom panel – The binding isotherms 




       
        Figure 9 – ITC binding data – reducing conditions. (A) The binding isotherm (red) is fit to the integrated  
        peaks (B - top panel) using a 1:1 binding model. The KD for this experiment is 4.8µM. 
 
 
Surface Plasmon Resonance 
  
 Numerous attempts to measure the binding affinity of the H-protein and 
LipL1/lipoyl-AMP were made using various buffers, at various concentrations, with 
additves such as BSA and soluble dextran to reduce non-specific binding and increase 
the signal to noise ratio. Table 7 summarizes the experimental conditions and 
observations from the various SPR experiments that I conducted.  I initially started the 
SPR binding experiments using a CM5 sensor chip which has a very high density of 
carboxymethylated dextran. Due to the very high level of non-specific binding that was 
observed when flowing LipL1 or HK96A as the analyte on the CM5 chip, I abandoned the 
CM5 chip for a CM3 sensor chip, which has shorter dextran polymers and significantly 
less carboxymethylated coupling sites. The sensorgram in figure 10 was generated using 
A B 
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a CM3 chip with 2946 response units (RU) of LipL1 bound to chip surface. A 7mg/mL 
LipL1 sample was diluted in 200µL of 10mM sodium acetate buffer pH 6 to a final 
concentration of 35µg/mL. Flow cell 1 on the CM3 chip was activated with EDC/NHS 
using the Biacore surface preparation wizard. The 35µg/mL LipL1 sample was then 
allowed to flow into the activated flow cell 1 at 5µL/min for 1 minute in order to 
accomplish covalent coupling of LipL1 to the surface of the sensor chip. After 1 minute 
the coupling reaction was immediately quenched by the the flow of 1M ethanolamine 
pH 8.5 for 7 minutes. The activation, coupling, and quenching was automated and 
performed in immediate succession by the Biacore surface preparation wizard. I allowed 
the activated chip to equilibrate in the running buffer (25mM K-Na PO4 pH 7.5, 65mM 
NaCl, 3mM EDTA, 0.005% (v/v) tween 20) for 4 hours before beginning binding studies. 
A 153µM HK96A solution was diluted to a final concentration of 5µM HK96A in running 
buffer with 1mM ATP and 100µM R-lipoic acid. Four, 2-fold serial dilutions of this 
sample were made yielding final concentrations of HK96A at 5µM, 2.5µM, 1.25µM 
625nM, and 312nM.  
 The binding experiments were carried out at 30µL/min, with an association time 
of 150 seconds, dissociation time of 180 seconds, and 2 separate 60 second quick 
injections of 1M NaCl per cycle in an attempt to dissociate any bound H-protein 
(regeneration). Three “blank” running buffer injections cycles were followed by a 
conjugation formation injection cycle consisting of just 1mM ATP and 100µM R-lipoic 
acid. This conjugation formation injection cycle was followed by another blank running 
buffer injection and finally the concentration series injections beginning with the 5µM 
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HK96A concentration and proceeding to the lower concentrations. For this experiment 
flow cell 4 was used a subtractive reference cell and the average of the running buffer 
blank injections were used to double reference the sensorgram. Flow cell 4 was 
unmodified by any coupling chemistry. The 5µM HK96A concentration injection data 
was inconsistent with the other concentration sensorgram curves and was removed 
prior to curve fitting. The association and dissociation of the analyte HK96A to bound 
LipL1/lipoyl-AMP can be seen below in figure 10. Binding data from this SPR experiment 
with LipL1 bound and HK96A under flow, yield a dissociation constant of 0.396µM under 
non-reducing conditions.   
 
Figure 10 – SPR binding data – non-reducing conditions. His6-LipL1 was immobilized on a CM3 chip and His6-HK96A 
was injected at four 2-fold serial dilutions (2.5µM-312.5nM). The blue curve is the HK96A 2.5µM concentration 
injection. The sensorgram plots response units on the Y-axis vs. time on the X-axis. Straight lines over the raw 
sensorgram curves indicate the best fit model used by Scrubber (Biologic) data processing software to derive an 




 By increasing the length of the sonication to three 1-minute iterations and by 
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adding 20mM imidazole to the lysis/running buffer during lysis and initial His-trap 
purifications, I was able to increase the yield and purity of PfHK96A. This is important for 
future work as HK96A was the limiting reagent in all of these experiments.   
 It is also worth noting that the size of the E. coli pellet during expression of 
HK96A was significantly reduced as compared to the size of the E. coli pellet during 
expression of Lipl1. This casual observation could indicate that the overexpression of Pf 
HK96A is toxic to E. coli, possibly due to competitive binding of the E. coli H-protein to 
LplA.  
 Although PfHK96A is roughly half the size of LipL1 it starts to elute from the S100 
gel filtration column about 10mL prior to LipL1. Typically, larger proteins tend to elute 
first, with smaller proteins eluting after. I performed one of the many HK96A gel 
purifications under reducing conditions to see if the early HK96A elution was due to 
dimerization through a disulfide bond. The reducing conditions had no effect on the gel 
filtration elution profile of HK96A, suggesting that HK96A is not a disulfide-linked dimer 
and therefore does not explain the early elution of HK96A. It may be that HK96A exists 
as a non-covalent dimer or has an unusual non-globular shape, resulting in a large 
hydrodynamic radius. It is worth noting that the Pf H-protein has an extended 40 amino 
acid tail not found in prokaryotic H-protein sequences and this region could be 
responsible for the unexpected elution profile from the gel filtration column. 
 The fusion protein constructs were not subjected to size exclusion 
chromatography prior to attempting crystallization. Getting a cleaner fusion protein, via 
gel filtration, prior to setting up crystal conditions could increase the chances of 
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producing ternary complex crystals that produce diffraction patterns at high enough 
resolution that lead to structural determination.  
 I moved away from ITC as a technique for determining the binding affinities for 
the protein-protein interaction due to that fact that each experiment consumed a large 
quantity of the purified HK96A protein used as the titrant. Typical yields for a 5-day long 
expression and purification from the gel filtration column were 250µL at 2mg/mL.  A 
2mg/mL concentration of HK96A is roughly 120µM. For the single experiment shown in 
Figure 8, 350µL of 40µM HK96A was used. I turned to SPR as a second method to 
determine the binding affinities of the proteins. Due to the highly sensitive nature of the 
technique very small quantities of proteins are needed. In theory, this should facilitate 
studying this interaction since HK96A is poor overexpressing protein and it is difficult to 
obtain large amounts.  
 SPR was not without its challenges. One of the major challenges of capturing the 
binding response was overcoming the response due to non-specific binding (NSB) of the 
analyte to the sensor chip surface. Theoretically, you can run SPR experiments with 
either binding partner bound to the chip surface. I tried multiple experiments with 
HK96A bound to the chip surface and flowing LipL1 as the analyte. I could not find 
conditions to overcome the LipL1 non-specific binding response. I settled on the amine 
coupling of LipL1 to the chip with HK96A as the analyte, as early experiments showed 
that HK96A had significantly less NSB. I was finally able to get a characteristic binding 
sensorgram after switching to a less carboxymethylated CM3 sensor chip. Results from 
the dilution series SPR experiment described above suggest a dissociation constant of 
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396nM under non reducing conditions, which is not far from the 97nM dissociation 
constant calculated under non-reducing conditions using ITC.  
  The binding data from the ITC experiments suggest that HK96A does indeed 
have an increased affinity for LipL1/lipoyl-AMP under non-reducing conditions as 
compared to reducing conditions. It remains to be seen whether the SPR experiment 
will yield reproducible results and a similar SPR experiment has yet to be conducted in 
the presence of a strong reducing agent, in order to compare the SPR dissociation 
constant under reducing conditions to that calculated by ITC. In the absence of 
structural data, it is impossible to explain why LipL1 preferentially lipoylates the H-
protein under non-reducing conditions vs. reducing conditions. In order to draw a 
complete picture of the mechanism of this pathway it is necessary to solve the crystal 
structures of the LipL1/lipoyl-AMP/H-protein complex as well as LipL1 in complex with 
dihydrolipoyl-AMP or its structural analogue 6,8 dichlorooctanoate to corroborate what 
we are seeing with the binding data of these two proteins.  
 Further inquiries into the actual role of the H-protein are also needed to 
understand the H-protein’s role after it is lipoylated. The P and T proteins of the GCS are 
absent in Plasmodium falciparum; therefore, the H-protein cannot perform its canonical 
role in glycine metabolism. It may be that the Pf H-protein has a function similar to that 
recently elucidated in Trichomonas vaginalis (46). In T. vaginalis, the P and T proteins 
are absent, with the H and L proteins being found in the hydrogenosome. It was shown 
that the H and L proteins work to deliver electrons to osmotically inducible protein, 
OsmC, which in turn reductively detoxifies harmful peroxides which are formed during 
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the interaction between the host’s immune response and T.vaginalis parasites (46).  
  
  



































Primers used for site directed mutagenesis, lysine to alanine mutation at position 
 96 of the Plasmodium falciparum H-protein. 
 
 Forward: 
 5’ – GATTGTATAGCGACAATTGAAAGTGTCgcgAGTGTAGGAGATGTATATACTCCTGT-3’ 
  
 Reverse: 
 5’ – ACAGGAGTATATACATCTCCTACACTcgcGACACTTTCAATTGTCGCTATACAATC-3’ 
 
Primers used for creating the adaptamer in order to change methionine at position 96 in 
the HK96M-LipL1 fusion protein to alanine, yielding the HK96A-LipL1 fusion protein 
 
 Forward: 
 5’ – Phos-CGAAAGTGTCgcgAGTGTAGGAGACGT – 3’ 
  
 Reverse: 
 5’ – Phos-CTCCTACACTcgcGACACTTTCGAT – 3’ 
  
Primers used for sequencing the pMALcHT plasmid. 
 
 Forward: 
 5’ – GCCCTGAAAGACGCGCAGAC – 3’ 
 
 Reverse: 






































Figure 11 – HK96M-LipL1 DNA sequence. Synthetic DNA sequence purchased from GeneArt which codes for the 
HK96M-LipL1 fusion protein. Red text represents the H-protein sequence, green text is the 17 amino acid linker, purple 
text is the LipL1 sequence. The highlighted bases represent the methionine that was mutated to alanine for this thesis 
work. The first and last underlined bases represent restriction enzyme (RE) cut sites EcoRI and HindIII respectively. The 
underlined bases on the same line with the highlighted methionine bases are the PvuI and AatII RE cut sites, which 
were used to insert the adaptamer coding for the alanine mutation. Underlined bases in the 17AA linker are the SpeI, 
KpnI, KpnI, and NheI RE cut sites which were used to adjust the length of the linker between the two proteins. 
 
MEFIKIEDGN LNNRKDMTNV KCKIGISNYG THKLGEIVYV DVAHNINDHV KKGDCIATIE 
SVMSVGDVYT PVSGKIININ NKIIDNVNLM NEQSEIDGWI MELETNQINE KEIMNISEYE 
KMCEEEEQNE EKKIQQNEIN CMEEKNKNKI FDINDMKNIE NKGQGGKTSS GTSGPSGPSG 
TSASNGPLVL VSNNQNIHFN LSLENFLLNN YNDLLKYLNI NTIEKFNEPI LFLWRNNRSI 
IIGKNQNIWS ECNLKNIKED GVLVARRFTG GGAVYHDLGN VCFTFLNNNI NTSSNFLIIL 
NTLKNHFNIE AKTQGRNDIT VNDQKCSGSA FKKIKDVFLH HGTILINLEK NILNKYLTPD 
KIKYIKHGVS SVNARTINLS EINNNITCEN LCIALIKEFT KFYEQNYNTN IIPNDITVHY 
IDQNNNITKN PEFLKYYNLL KDWDWCYGKT PKFQNHIWKQ FTFGKLELFF NVSNGFIKDG 
NIFSDCLDIN LIDHLKSIFN NDIKYSKEDI SIFFKKLNVE NKNYLDEVRS WILQEL	














































































Chip Type Buffer Coupling Ligand Analyte Observations Results 




Capture 6x His-LipL1 GST-HK96M Drifting  
Baseline 
NSB 
No kinetic data 
Affinity based on equilibrium concentration 
KD- 310nM from first pass experiment 
Ni-NTA chip costly, highly reusable, no need for regen 






6x His-LipL1 6xHis-HK96A Non specific  
binding  
High NSB with this chip. 
Could be due to amine coupling LipL1 @ pH 5 
With 100-300RU of LipL1 bound insignificant binding 
response 






6xHis-HK96A 6xHis-LipL1 Non specific  
binding 
Inconclusive 
Too much NSB. 
LipL1 seems to be very sticky. 






6x His-HK96A 6xHis-LipL1 Non-specific 
 binding  
Less NSB than with CM5 chip. CM3 chip has shorter 
dextran.  
LipL1 has high NSB. Could not be overcome with 
soluble dextran or BSA 






6x His-LipL1 6xHis-HK96A Decent  
sensorgrams 
 
At 5M analyte plateaus at low RU 
At 2.5µM -600nM analyte conc. yields characteristic 
binding sensorgram 
Coupled 2900RU of LipL1 to surface-may be necessary 
in order to get decent signal due to random and 
cross coupling to dextran matrix 








Buffer Cofactors Titrant Sample cell TCEP N KD Average 
KD 






40µM HK96A 2µM LipL1 NO 1.1 0.142µM  
- 






40µM HK96A 2µM LipL1 NO 0.91 0.071µM  
- 






40µM HK96A 2µM LipL1 NO 0.95 0.077µM  
- 
        0.097µM 






40µM HK96A 2µM LipL1 YES 
5mM 
0.06 4.83µM  
- 
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